Sunshine Biopharma Capital Expenditures (CapEx) Growth & History (SBFM)

Sunshine Biopharma's capital expenditures (capex) was $174,491 for fiscal 2025.

View full Sunshine Biopharma company overview

Sunshine Biopharma annual capital expenditures (capex) history

Sunshine Biopharma annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20252025-12-31$174,491−$1.5M−89.47%
20242024-12-31$1.7M$1.6M+1914.63%
20232023-12-31$82,251−$111,731−57.60%
20222022-12-31$193,982$193,982
20212021-12-31$0−$1,191
20202020-12-31$1,191$331+38.49%
20192019-12-31$860−$17,990−95.44%
20182018-12-31$18,850$15,132+406.99%
20172017-12-31$3,718$279+8.11%
20162016-12-31$3,439−$1,354−28.25%
20152015-12-31$4,793$4,793
20142014-12-31$0

Sunshine Biopharma capital expenditures (capex) trends

Over the last five fiscal years, Sunshine Biopharma's capital expenditures (capex) increased from $1,191 to $174,491, a change of $173,300. The latest reported quarter, Q2 2026, shows $7,015.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Sunshine Biopharma source filings ↗

Community posts

It’s quiet here.

No posts about SBFM yet. Start the conversation.

Write the first post